Jeffrey Chamberlain, PhD, will receive the Legacy Award for Achievement in Research by The Muscular Dystrophy Association at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference on Monday, March 4, 2024. This year’s award is for achievement in translational research.
Chamberlain is recognized for his research on gene therapy for Duchenne muscular dystrophy at the Institute for Stem Cell and Regenerative Medicine at the University of Washington. The Chamberlain Laboratory studies the mechanisms leading to muscular dystrophies, the structure and function of dystrophin (mutated in Duchenne muscular dystrophy) among the most common inherited diseases, and approaches to therapy. He is also the president of the American Society for Gene and Cell Therapy.
The Muscular Dystrophy Association is a health organization for people living with muscular dystrophy, ALS and related neuromuscular diseases and is known for accelerating research and advancing care.
